 SHANGHAI and HONG KONG, July 5, 2021 PRNewswire -- Antengene Corporation Limited Antengene, SEHK: 6996.HK, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class andor best-in-class therapeutics in hematology and oncology, recently announced that Chinas National Medical Products Administration NMPA has accepted the Investigational New Drug IND application for single agent selinexor, a first-in-class orally available Exportin 1 XPO1 inhibitor, for the treatment of patients with myelofibrosis MF in China. MF is a clonal hematologic neoplasm which can emerge either as primary MF, polycythemia vera PV or essential thrombocythemia ET1. 